Z-LEHD-fmk

Research use only, not for human use.

Z-LEHD-FMK is a selective and potent caspase-9 inhibitor that protects against reperfusion injury and slows apoptosis. Z-LEHD-FMK exhibits antitumor and neuroprotective activity.

Z-LEHD-FMK is a selective and irreversible inhibitor of caspase-9, protects against lethal reperfusion injury and attenuates apoptosis. Z-LEHD-FMK exhibits the neuroprotective effect in a rat model of spinal cord trauma.

Z-LEHD-FMK (20 μM; pretreated for 30 min) completely protects HCT116 and 293 cells from TRAIL-induced toxicity.Z-LEHD-FMK (20 μM ; 6 h) protects normal human hepatocytes from TRAIL-induced apoptosis.Apoptosis Analysis Cell Line:SW480, H460, HCT116 and 293 cells Concentration:20 μM Incubation Time:Pretreated for 30 min Result:Protected HCT116 and 293 cells from TRAIL-induced apoptosis.Western Blot Analysis Cell Line:HCT116, SW480 cells Concentration:20 μM Incubation Time:2 h Result:Protected procaspase 3 from cleavage in HCT116 cells but not in SW480 cells, especially at the 16-h time point.

Z-LEHD-FMK (0.8 μmol/kg; i.v. for 7 d) protects neurons, glia, myelin, axons, and intracellular organelles in spinal cord injury (SCI) rats.Animal Model:Male Wistar albino rats (250-350 g) with SCI Dosage:0.8 μmol/kg Administration:I.v. for 1 or 7 days Result:Decreased the mean apoptotic cell count at 24 hours and 7 days postinjury.

——

Apoptosis

Caspase

Caspase | Apoptosis

——

——

210345-04-3

690.72

C32H43FN6O10

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (144.78 mM)

COC(=O)CC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)OCc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(=O)OC)C(=O)CF

——

(-20℃)

With Ice Pack

≥ 2 years